Biotech Stock News: NervGen Pharma (TSXV: NGEN) (OTCQX: NGENF) Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291

Vancouver, British Columbia – March 15, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received approval from the Safety Review Committee to advance to the second cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291.